Why Do Some People Get Dementia In Their 40s?

SAN FRANCISCO — Frontotemporal dementia (FTD) typically strikes adults in their 40s to 60s, often when they’re at the peak of their careers and family responsibilities. Unlike Alzheimer’s disease, which primarily affects memory, FTD attacks the frontal and temporal lobes of the brain, dramatically altering personality, behavior, and language skills.

Despite being one of the most common causes of early-onset dementia, scientists still don’t fully understand what drives FTD progression or how to stop it. Now, a new study published in Nature Aging has uncovered new molecular signatures of the disease by analyzing over 4,000 proteins in the cerebrospinal fluid (CSF) of patients with genetic forms of FTD.

Mapping FTD Proteins

Researchers from the University of California, San Francisco and their collaborators collected cerebrospinal fluid, the clear liquid that bathes the brain and spinal cord, from 116 people carrying genetic mutations known to cause FTD and 39 family members without these mutations. Using advanced protein measurement technology, they identified over 4,000 proteins and mapped how these proteins interact with each other in different stages of the disease.

he researchers found 31 groups of proteins that work together in the brain. Four of these groups stood out for their strong links to dementia severity. One group of proteins, tied to how cells process genetic instructions, was more active in people with FTD. Meanwhile, three other groups—linked to brain cell communication, nerve growth, and the brain’s cleanup system—were less active.

Some protein changes appeared even in people who carried the FTD-causing genetic mutations but hadn’t yet developed symptoms. This suggests that molecular changes begin years before noticeable cognitive decline, potentially opening a window for early intervention.

Different genetic forms of FTD showed distinctive patterns. Carriers of mutations in the GRN gene showed early elevations in RNA splicing proteins, which help process genetic information. Those with MAPT mutations (which cause accumulation of abnormal tau protein) showed unique increases in proteins involved in the extracellular matrix, the scaffolding between brain cells. These distinct patterns reflect the different ways these genetic mutations damage the brain.

To validate their findings, researchers tested whether similar protein patterns could be found in patients with sporadic forms of FTD (cases without a known genetic cause). They found similar protein patterns in both inherited and non-inherited cases of FTD, suggesting these changes are part of the core process that drives the disease.

The study pinpointed key proteins that seem to play a central role in these brain changes, and could one day help doctors track or treat the disease. One protein, called NPTX2, had the strongest link to worsening thinking and memory. Others were involved in processing genetic material or maintaining the brain’s structural support system.

Distinguishing FTD from Other Brain Diseases

Researchers also compared their FTD protein profiles with those previously found in Alzheimer’s and Parkinson’s diseases. While some overlap existed, particularly in proteins related to neurodegeneration, many FTD-associated changes were unique to this condition. For example, RNA processing proteins were distinctly elevated in FTD but not in other neurodegenerative diseases.

By mapping out the protein changes linked to FTD, scientists have taken an important step toward new treatments. Next steps could include creating tests that can measure these key proteins to see if they can help predict how the disease will progress or how well someone might respond to future therapies.

For families affected by FTD, effective treatments may still be years away, but each discovery like this brings us one step closer to therapies that could slow or halt this devastating condition.